Tussilago farfara

Tussilago farfara (coltsfoot) contains tussilagone and pyrrolizidine alkaloids as primary bioactive compounds, with tussilagone demonstrating anti-inflammatory activity by inhibiting NF-κB signaling and suppressing pro-inflammatory cytokines TNF-α and IL-6. Traditional use centers on respiratory conditions including cough and bronchitis, though robust human clinical trial data remain absent.

Origin & History

Tussilago farfara L. (coltsfoot) is a perennial herbaceous plant native to Europe, Asia, and North America, with its dried flower buds (Farfarae Flos) used medicinally. The plant is sourced from wild or cultivated populations, with extracts typically prepared via infusion, decoction, or solvent extraction using ethanol or water.

Historical & Cultural Context

T. farfara has been used in traditional Chinese, European, and folk medicine for centuries to treat respiratory disorders such as cough, asthma, and bronchopneumonia. It has also been traditionally applied for allergies, liver disease, and gastrointestinal issues as an expectorant and antitussive.

Health Benefits

• Anti-inflammatory effects: Tussilagone reduced TNF-α, IL-6, and NF-κB activation in mouse colitis models (PMID: 30142311) - preliminary evidence
• Respiratory support: Traditional use for cough, asthma, and bronchopneumonia, though clinical trials are lacking - traditional evidence only
• DNA protection: Polysaccharides protected against chemotherapy-induced DNA damage in preclinical studies (PMID: 30488215) - preliminary evidence
• Antioxidant activity: Extracts demonstrated DPPH scavenging and enzyme inhibition (>70% urease inhibition) in vitro - preliminary evidence
• Immunomodulation: Polysaccharides reduced CD279 and CD274 expression in lymphocytes, potentially mitigating chemotherapy side effects - preliminary evidence

How It Works

Tussilagone, a sesquiterpene enoate from Tussilago farfara, inhibits NF-κB activation and downstream transcription of pro-inflammatory cytokines including TNF-α and IL-6, as demonstrated in murine colitis models (PMID: 30142311). The plant's polysaccharides and flavonoids may contribute to mucilaginous soothing effects on airway epithelium, potentially modulating mast cell degranulation and histamine release relevant to asthma pathophysiology. Pyrrolizidine alkaloids (PAs) such as senkirkine and senecionine are hepatotoxic via CYP3A4-mediated bioactivation to pyrrolic ester metabolites that form DNA adducts and cause hepatic veno-occlusive disease.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified in the available research. Evidence is limited to preclinical studies including mouse colitis models (PMID: 30142311), rabbit inflammation models (PMID: 39442825), and in vitro studies on human adipose stem cells at 5 μg/ml (PMID: 39442825).

Clinical Summary

Evidence for Tussilago farfara is predominantly preclinical and traditional, with no large-scale randomized controlled trials in humans identified. Mouse colitis models demonstrate tussilagone reducing colonic NF-κB activation and inflammatory cytokine levels at tested doses, representing preliminary mechanistic evidence only. Traditional ethnopharmacological use across European and Asian systems supports its role in managing productive cough and bronchospasm, but these reports lack controlled methodology. The presence of hepatotoxic pyrrolizidine alkaloids has shifted regulatory and research focus toward safety over efficacy validation, limiting modern clinical investigation.

Nutritional Profile

Tussilago farfara (coltsfoot) contains a range of bioactive compounds with limited quantitative nutritional data. Leaves and flowers contain polysaccharides (mucilage), primarily consisting of inulin and water-soluble polysaccharides estimated at 8-15% dry weight, which contribute to its demulcent properties. Pyrrolizidine alkaloids (PAs) are present at concerning levels, including senkirkine and senecionine, reported at approximately 0.015-0.1% dry weight in leaves and higher concentrations in roots — these are hepatotoxic and restrict safe use. Flavonoids include rutin, hyperoside, kaempferol, and quercetin derivatives, with total flavonoid content estimated at 0.5-1.2% dry weight. Tussilagone (a sesquiterpene) is a key anti-inflammatory bioactive compound isolated from flower buds. Tannins are present at approximately 5-10% dry weight. Zinc and calcium are detectable mineral constituents, though specific concentrations are not well-documented in nutritional databases. Vitamins are not significantly characterized. Chlorogenic acid and caffeic acid derivatives contribute antioxidant activity. Carotenoids (beta-carotene precursors) are present in the yellow flowers. Bioavailability of polysaccharides is low due to limited digestibility; flavonoid bioavailability is moderate. Overall, this plant is not used as a dietary nutrient source and is classified as a medicinal herb with significant safety limitations due to PA content.

Preparation & Dosage

No clinically studied human dosage ranges are available as human trials are absent. Traditional preparations include infusions and decoctions of flower buds. Preclinical studies used 5 μg/ml extract for in vitro cytoprotection. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Licorice root, Thyme, Marshmallow root, Mullein, Ivy leaf

Safety & Interactions

Tussilago farfara contains hepatotoxic pyrrolizidine alkaloids (PAs), particularly senkirkine and senecionine, which are bioactivated by CYP3A4 to reactive pyrrole intermediates capable of forming DNA adducts, causing hepatic veno-occlusive disease and carrying potential carcinogenic risk with chronic exposure. It is contraindicated in pregnancy and lactation, as PAs cross the placental barrier and are embryotoxic in animal studies. Concurrent use with other hepatotoxic substances, including acetaminophen, alcohol, and azole antifungals that inhibit CYP3A4 clearance, may amplify hepatotoxic risk. Several European regulatory bodies, including Germany's Commission E, have restricted or withdrawn approval for internal use; PA-free standardized preparations exist but require verified alkaloid-free certification before use.